Phase II study of combination chemotherapy with @entity1205 and @entity3003 for locally advanced or recurrent XXXX .

@entity1 @entity137 @entity882 @entity5 @entity3003 @entity957 @entity420 @entity1503 @entity1358 @entity1398 @entity1205
The efficacy and @entity137 of combination chemotherapy with @entity1205 + @entity3003 were evaluated in @entity1 with locally advanced or recurrent @entity5 . A total of 71 @entity1 with @entity5 were enrolled into this trial, and 66 @entity1 were considered eligible. The @entity1 were administered @entity1205 at 60 mg/m2 followed by @entity3003 based on area under the curve of 6, both by intravenous infusion, every 3 weeks, with the treatment repeated for 1 to 6 cycles depending on the goal of the therapy. The response was evaluated based on the Response Evaluation Criteria in @entity5 criteria. @entity137 to chemotherapy was evaluated according to the National @entity5 Institute Common @entity137 Criteria. Of the 66 eligible @entity1 , 62 had locally @entity5 with no history of previous treatment, whereas 4 @entity1 had recurrent @entity5 . A total 149 cycles of chemotherapy were administered, with a median of 2.3 cycles (range, 1-6) per @entity1 . The overall clinical response rate was 63.7% (44/66, 95% confidence interval, 52.1-75.3). In the neoadjuvant chemotherapy setting, the overall clinical response rate was 69.3% (43/62; 43/62, 95% confidence interval, 57.8-80.8), and the response rates in @entity1 with @entity957 and @entity1358 were 69.7% (23/33, 95% confidence interval, 54.0-85.4) and 68.9% (20/29, 95% confidence interval, 52.1-85.7), respectively. On the other hand, in @entity1 with recurrent @entity5 , the overall response rate was 25.0% (1/4, 95% confidence interval, -17.4 to 67.4). Nonhematological @entity137 were mainly grade 1 or 2. @entity1503 was encountered mostly in the form of @entity1398 and @entity882 . Combination chemotherapy with @entity1205 + @entity3003 is a safe and well-tolerated treatment for @entity1 with @entity5 and is effective against not only @entity957 , but also @entity420 .
